Replies to post #131866 on Biotech Values

[hptaxis]

How do you see MNTA driving the process other than lobbying?

Also, MNTA's accumulating patent portfolio appears to be a powerhouse in its own right. With or without mC approval, this makes the company attractive. Should mC be approved, I envision a bidding war for MNTA.

[DewDiligence]

Currently total US biologics market in 2015 is expected to be about $100B - but I'd expect >50% to still be under patent protection.

You just did a bait & switch, which I presume was unintentional. In #msg-69353436 your time frame was 2017-2019 while in #msg-69353983 it is 2015. A difference of 2-4 years matters a lot in this discussion.